



Myrexis to Present at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium

SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced it will present two posters at the 2011 European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," to be held November 12 — 16, 2011 in San Francisco, CA.

The results to be presented include the findings from a recently completed Phase 1 clinical study of MPC-3100, the Company's fully synthetic, orally bioavailable heat shock protein 90 (Hsp90) inhibitor and preclinical data from MPC-8640, the lead compound in its nicotinamide phosphoribosyltransferase (Namt) inhibitor program.

Title: Phase 1 Study of Hsp90 Inhibitor MPC-3100 in Subjects with Refractory or Recurrent Cancer
Authors: W. Samlowski, K. Papadopoulos, A. Olszanski, K. Zavitz, D. Cimbor, S. Shawbell, A. Balch, G. Mather, A. Beelen
Date & Time: Sunday Nov 13, 2011 12:30 PM - 2:30 PM Pacific Time
Location: West Hall, Level One, Moscone Center West
Poster: Session A, clinical trials 1, #A96

Title: Pharmacokinetics, Anti-Tumor Activity and Therapeutic Index of Nampt Inhibitor MPC-8640 in Mice
Authors: R. Carlson, J. Willardsen, J. Lockman, C. Bradford, J. Patton, D. Papac, J. Boniface, K. Yager and V. Baichwal
Date & Time: Monday Nov 14, 2011 12:30 PM - 2:30 PM Pacific Time
Location: West Hall, Level One, Moscone Center West
Poster Number: Session B, metabolism, #B137

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.

Additional information about Myrexis is available through its corporate website, www.myrexis.com.

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=9929>

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes, expected development, and potential efficacy of Myrexis' product candidates. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2011, which was filed with the Securities and Exchange Commission on September 13, 2011, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Wayne Laslie

Chief Operating Officer

801-214-7822

investor.relations@myrexix.com

The Ruth Group

Stephanie Carrington/Joshua Drumm, PhD (investors)

(646) 536-7017/(646) 536-7006

scarrington@theruthgroup.com/jdrumm@theruthgroup.com

Victoria Aguiar (media)

(646) 536-7013

vaguiar@theruthgroup.com